R. Wei

408 total citations
17 papers, 328 citations indexed

About

R. Wei is a scholar working on Oncology, Surgery and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, R. Wei has authored 17 papers receiving a total of 328 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Surgery and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in R. Wei's work include Bone health and treatments (11 papers), Management of metastatic bone disease (9 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). R. Wei is often cited by papers focused on Bone health and treatments (11 papers), Management of metastatic bone disease (9 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). R. Wei collaborates with scholars based in United States, United Kingdom and Spain. R. Wei's co-authors include Ignacio Durán, H. Wang, Robert E. Coleman, Karim Fizazi, Piotr Milecki, Siobhan Ng, Mitchell R. Smith, Diana Lüftner, Arun Balakumaran and K. Pittman and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

R. Wei

16 papers receiving 324 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R. Wei United States 8 253 129 106 88 37 17 328
Fabio Catalano Italy 11 142 0.6× 119 0.9× 79 0.7× 48 0.5× 31 0.8× 37 329
Shinya Maita Japan 10 137 0.5× 146 1.1× 82 0.8× 32 0.4× 14 0.4× 25 370
Nilesh Mehta United States 5 319 1.3× 100 0.8× 55 0.5× 50 0.6× 18 0.5× 6 389
B. Massuti Sureda Spain 5 263 1.0× 125 1.0× 46 0.4× 19 0.2× 47 1.3× 26 350
S. Jagdev United Kingdom 6 406 1.6× 152 1.2× 71 0.7× 192 2.2× 4 0.1× 8 469
Bertrand Filleul Belgium 8 69 0.3× 84 0.7× 33 0.3× 36 0.4× 65 1.8× 14 265
Nian Lu China 10 130 0.5× 84 0.7× 64 0.6× 145 1.6× 12 0.3× 33 296
Pierluigi Bonfili Italy 10 113 0.4× 141 1.1× 146 1.4× 36 0.4× 61 1.6× 26 348
David R. Trevarthen United States 9 164 0.6× 204 1.6× 251 2.4× 27 0.3× 44 1.2× 13 516

Countries citing papers authored by R. Wei

Since Specialization
Citations

This map shows the geographic impact of R. Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Wei more than expected).

Fields of papers citing papers by R. Wei

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Wei. The network helps show where R. Wei may publish in the future.

Co-authorship network of co-authors of R. Wei

This figure shows the co-authorship network connecting the top 25 collaborators of R. Wei. A scholar is included among the top collaborators of R. Wei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Wei. R. Wei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Wei, R., et al.. (2024). Associations between bone mineral density and abdominal aortic calcification: Results of a nationwide survey. Nutrition Metabolism and Cardiovascular Diseases. 34(6). 1488–1495. 3 indexed citations
2.
Wei, R., Yulong Tian, Wei Xia, et al.. (2023). Adaptive Ultra-Hypofractionated Whole-Pelvic Radiotherapy in High-Risk and Very High-Risk Prostate Cancer on 1.5-1.5 MR Linac: The Estimated Delivered Dose and Early Toxicity Results. International Journal of Radiation Oncology*Biology*Physics. 117(2). e384–e384.
3.
Tam, Constantine S., M. Wang, David Simpson, et al.. (2019). UPDATED SAFETY AND EFFICACY DATA IN THE PHASE 1 TRIAL OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111). Hematological Oncology. 37(S2). 245–247. 24 indexed citations
4.
5.
Durán, Ignacio, Amit Bahl, Aftab Mahmood, et al.. (2016). Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study. European Journal of Cancer Care. 26(6). e12452–e12452. 19 indexed citations
6.
7.
Smith, Mitchell R., Robert E. Coleman, Laurence Klotz, et al.. (2014). Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Annals of Oncology. 26(2). 368–374. 117 indexed citations
8.
Hechmati, Guy, S. Cure, Vito Lorusso, et al.. (2013). Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study. Journal of Medical Economics. 16(5). 691–700. 46 indexed citations
9.
Durán, Ignacio, et al.. (2013). Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours. Clinical & Translational Oncology. 16(3). 322–329. 21 indexed citations
10.
Yue, Tao, Ping Zeng, R. Wei, et al.. (2013). Primary immunodeficiency in south China: clinical features and a genetic subanalysis of 138 children.. PubMed. 23(5). 302–8. 13 indexed citations
11.
Fizazi, Karim, Janet E. Brown, Michael A. Carducci, et al.. (2012). Denosumab in Patients with Metastatic Prostate Cancer Previously Treated with Denosumab or Zoledronic Acid: 2-Year Open-Label Extension Phase Results from the Pivotal Phase 3 Study. Annals of Oncology. 23. ix309–ix309. 3 indexed citations
12.
Hechmati, Guy, Amit Bahl, Diana Lüftner, et al.. (2011). PCN76 SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES LEAD TO CONSIDERABLE HEALTH RESOURCE UTILISATION IN EUROPE: ANALYSIS OF A MULTINATIONAL OBSERVATIONAL STUDY. Value in Health. 14(3). A168–A168. 3 indexed citations
13.
14.
Bahl, Amit, Ignacio Durán, Guy Hechmati, et al.. (2011). Health resource utilization (HRU) associated with skeletal-related events (SREs) in patients with bone metastases (BM): Results of a prospective multinational observational study.. Journal of Clinical Oncology. 29(15_suppl). e16523–e16523. 3 indexed citations
15.
Wagstaff, John, RE Hawkins, Paul Nathan, et al.. (2011). Sunitinib (SU) treatment (trx) patterns and toxicity in patients (pts) with advanced renal cell carcinoma (RCC) in United Kingdom (UK).. Journal of Clinical Oncology. 29(15_suppl). e15150–e15150. 1 indexed citations
16.
17.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fabio Catalano Breakdown of academic impact, for papers by Shinya Maita Breakdown of academic impact, for papers by Nilesh Mehta Breakdown of academic impact, for papers by B. Massuti Sureda Breakdown of academic impact, for papers by S. Jagdev Breakdown of academic impact, for papers by Bertrand Filleul Breakdown of academic impact, for papers by Nian Lu Breakdown of academic impact, for papers by Pierluigi Bonfili Breakdown of academic impact, for papers by David R. Trevarthen
Rankless by CCL
2026